Sutro Biopharma Inc. (STRO)
Sutro Biopharma Statistics
Share Statistics
Sutro Biopharma has 83.78M shares outstanding. The number of shares has increased by 2.42% in one year.
| Shares Outstanding | 83.78M |
| Shares Change (YoY) | 2.42% |
| Shares Change (QoQ) | 1.6% |
| Owned by Institutions (%) | 77.46% |
| Shares Floating | 75.61M |
| Failed to Deliver (FTD) Shares | 200 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 3.85M, so 4.67% of the outstanding shares have been sold short.
| Short Interest | 3.85M |
| Short % of Shares Out | 4.67% |
| Short % of Float | 5.05% |
| Short Ratio (days to cover) | 3.69 |
Valuation Ratios
The PE ratio is -0.62 and the forward PE ratio is -0.55. Sutro Biopharma's PEG ratio is -0.01.
| PE Ratio | -0.62 |
| Forward PE | -0.55 |
| PS Ratio | 2.28 |
| Forward PS | 0.8 |
| PB Ratio | 3.17 |
| P/FCF Ratio | -0.73 |
| PEG Ratio | -0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Sutro Biopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.6, with a Debt / Equity ratio of 0.52.
| Current Ratio | 2.6 |
| Quick Ratio | 2.6 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | -0.12 |
| Debt / FCF | -0.12 |
| Interest Coverage | -7.67 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $200.14K |
| Profits Per Employee | $-733.75K |
| Employee Count | 310 |
| Asset Turnover | 0.16 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 2.36M |
| Effective Tax Rate | -1.05% |
Stock Price Statistics
The stock price has increased by -87.82% in the last 52 weeks. The beta is 1.22, so Sutro Biopharma's price volatility has been higher than the market average.
| Beta | 1.22 |
| 52-Week Price Change | -87.82% |
| 50-Day Moving Average | 1.46 |
| 200-Day Moving Average | 2.87 |
| Relative Strength Index (RSI) | 24.52 |
| Average Volume (20 Days) | 1.35M |
Income Statement
In the last 12 months, Sutro Biopharma had revenue of 62.04M and earned -227.46M in profits. Earnings per share was -2.96.
| Revenue | 62.04M |
| Gross Profit | 62.04M |
| Operating Income | -238.45M |
| Net Income | -227.46M |
| EBITDA | -186.81M |
| EBIT | -194.03M |
| Earnings Per Share (EPS) | -2.96 |
Balance Sheet
The company has 190.3M in cash and 23.15M in debt, giving a net cash position of 167.15M.
| Cash & Cash Equivalents | 190.3M |
| Total Debt | 23.15M |
| Net Cash | 167.15M |
| Retained Earnings | -786.87M |
| Total Assets | 387.21M |
| Working Capital | 211.42M |
Cash Flow
In the last 12 months, operating cash flow was -191.54M and capital expenditures -3.1M, giving a free cash flow of -194.64M.
| Operating Cash Flow | -191.54M |
| Capital Expenditures | -3.1M |
| Free Cash Flow | -194.64M |
| FCF Per Share | -2.53 |
Margins
Gross margin is 100%, with operating and profit margins of -384.34% and -366.62%.
| Gross Margin | 100% |
| Operating Margin | -384.34% |
| Pretax Margin | -362.81% |
| Profit Margin | -366.62% |
| EBITDA Margin | -301.1% |
| EBIT Margin | -384.34% |
| FCF Margin | -313.71% |
Dividends & Yields
STRO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for STRO is $10, which is 1512.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 1512.9% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | -3.59 |
| Piotroski F-Score | 2 |